Breast-milk therapy for Microbiome disease makes BioGaia smile

11/09/2015 - 2 minutes

BioGaia is a leading microbiome biotech from Stockholm (Sweden) who use the beneficial bacterium Lactobacillus reuteri to produce probiotic consumables. The biotech is currently investing millions in another Stockholm biotech, Infant Bacterial Therapeutics (IBT). IBT is developing a therapy for Necrotising enterocolitis (NEC) derived from L.reuteri, which is found in human breast-milk.biogaia_1

BioGaia is a biotech conglomerate with worldwide operations extending over 90+ countries. To extend their microbiome portfolio, an additional €461K investment will go into IBT, a biotech looking to launch a safety and tolerability study for their IBP-9414 product line. It has already been announced that BioGaia will invest a further €3.7M (SEK 35M) into this project, with a total investment currently standing at around €8.8M.

Necrotising enterocolitis (NEC) is a condition which is responsible for a large proportion of premature death in infants (around 3700 babies in Europe alone). NEC causes parts of the infant’s bowl to die, which has a severe knock-on effect in their health and other organs.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!